COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
04/09/2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated [...]
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique
04/09/2025
L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, [...]
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
04/09/2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated [...]
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique
04/09/2025
L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, [...]
Kuros Biosciences announces changes in the Board of Directors
04/09/2025
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of Directors Schlieren (Zurich), Switzerland, September 4, 2025 – Kuros Biosciences (“Kuros” or the “ [...]
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
04/09/2025
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates Compelling kidney function data and meta-analysis from two Phase 2 studies, VIVIAD and VIVA-MIND, presented in oral presentation at ERA [...]
JUST ON SLEEP Officially Launches on Shopee Singapore, Redefining Sleep Safety and Wellness
04/09/2025
SINGAPORE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- JUST ON SLEEP, a smart contactless sleep monitoring device developed by Sewon Intelligence, has recently launched in Singapore via Shopee, making advanced sleep wellness and [...]
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
04/09/2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note [...]
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
03/09/2025
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to [...]
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
03/09/2025
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral [...]
Sotera Health Announces Secondary Offering of Common Stock
03/09/2025
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $ [...]
Artelo Biosciences Announces Proposed Underwritten Public Offering
03/09/2025
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
03/09/2025
Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27 th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – [...]
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
03/09/2025
Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock [...]
Pennant Announces Home Health Acquisition in Wyoming
03/09/2025
EAGLE, Idaho, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/09/2025
SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
03/09/2025
PARIS, 03 sept. 2025 (GLOBE NEWSWIRE) -- (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
03/09/2025
PARIS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
03/09/2025
Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine [...]

Pages